ArticleFrontiers in oncology2025
Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In non-small cell lung cancer (NSCLC), ALK tyrosine kinase inhibitors (TKIs) have been associated with significant weight gain, predominantly in fat tissues. To date, only one case report has evaluated the impact of pharmacologic intervention on managing this drug-related side effect, with concerns about potential interactions with oncological treatments. No information is available regarding non-pharmacological intervention. Case description: A 43-year-old man affected by metastatic ALK-rearranged NSCLC developed Grade 1 weight gain 1.5 months after starting Lorlatinib. The patient participated in a structured exercise program to manage this side effect. The program lasted 6 months and consisted of aerobic activities, including continuous and interval training, as well as resistance exercises using body weight/isotonic machines, performed at moderate to somewhat vigorous intensity, twice a week. Assessments were performed at three and six months, and included physical fitness and patient-reported outcomes parameters. Although the weight remained stable, body composition analysis, via bioimpedance and CT scan, revealed a decrease in fat tissue and an increase in muscle mass. Moreover, the patient reported improvements in physical fitness, especially in cardiorespiratory fitness, muscle strength, endurance, and flexibility. Among the patient-reported outcomes, different domains of quality of life improved. Conclusion: This case may represent the backbone for further interventional studies aimed at determining the real efficacy of exercise intervention in preventing or controlling weight gain in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.